Drug intelligence / Profile preview

PrevaHAV

Development stage: Unknown
Lead developer: Incepta Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PrevaHAV is an inactivated hepatitis A vaccine developed and manufactured by Incepta Pharmaceuticals Ltd. (Incepta Vaccines). It is composed of a purified sterile suspension of the hepatitis A virus that has been cultured in human diploid cells, purified, and inactivated using formaldehyde. The vaccine is adsorbed onto aluminium hydroxide to serve as an adjuvant. PrevaHAV is indicated for active immunization against hepatitis A virus (HAV) infection and is approved for use in individuals aged 12 months and older. The standard vaccination regimen consists of two doses administered six months apart to induce protective antibody levels.

Brand names: PrevaHAV
Other names: Preva HAVInactivated Hepatitis A vaccine BP

Beyond the preview

Go deeper on PrevaHAV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrevaHAV.

Explore the full profile